Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
The producer of food additives and pharmaceutical ingredients is aiming to raise fresh capital to support its drive to become a developer of innovative drugs Key takeaways: R&D costs have…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
BRIEF: Shimai Pharma gets CSRC nod for Hong Kong IPO
Zhejiang Shimai Pharmaceutical Co. Ltd., a developer of T-cell engager (TCE) therapies, has been cleared by the China Securities Regulatory Commission (CSRC) for its overseas listing, marking an important step…
Innovent’s $10.5 billion deal marks new model for China drugmakers
The Chinese biotech has added a major Pfizer collaboration to its growing roster of global deals, this time with a tighter commercial and profit-sharing partnership Key Takeaways: Co-commercialization deals…
BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
Drug development services company WuXi Biologics (Cayman) Inc. (2269.HK) announced on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
BRIEF: Voicecomm raises $40 million via share placement at 20% discount
2495.HK
-
BRIEF: Time Interconnect raises $209 million in share placement at 15% discount
1729.HK
- BRIEF: CANbridge raises $26 million in share sale to WuXi Bio at 14.7% discount
